背景:多发性硬化症(MS)是一种免疫介导的疾病,与几种危险因素有关,例如各种病毒感染。我们进行这项研究是为了确定COVID-19感染与MS严重程度之间的关系。
方法:在一项病例对照研究中,我们招募了复发缓解型多发性硬化(RRMS)患者.在登记阶段结束时,根据COVID-19PCR阳性将患者分为两组。对每位患者进行前瞻性随访12个月。人口统计,临床,在常规临床实践期间收集既往病史.每6个月进行一次评估;在登记时和12个月后进行MRI检查。
结果:三百六十二名患者参与了这项研究。合并COVID-19感染的MS患者的MRI病灶数量(p:0.019,OR(CI):6.37(1.54-26.34))和EDSS评分(p:0.017)明显增加,但总的年复发率或复发率没有差异。COVID-19感染与EDSS进展(p:0.02)和新的MRI病变数量(p:0.004)呈正相关,并预测新的MRI病变数量的可能性为5.92(p:0.018)。
结论:COVID-19可能导致RRMS人群的残疾评分更高,并且与MRI成像中出现新的Gd增强病变有关。然而,两组间随访期间复发次数无差异.
Multiple sclerosis (MS) is an immune-mediated disease that has been related to several risk factors such as various viral infections. We carried out this study in order to establish a relationship between COVID-19 infection and MS severity.
In a
case-control study, we recruited patients with relapsing-remitting multiple sclerosis (RRMS). Patients were divided into two groups based on positive COVID-19 PCR at the end of the enrollment phase. Each patient was prospectively followed for 12 months. Demographical, clinical, and past medical history were collected during routine clinical practice. Assessments were performed every six months; MRI was performed at enrollment and 12 months later.
Three hundred and sixty-two patients participated in this study. MS patients with COVID-19 infection had significantly higher increases in the number of MRI lesions (p: 0.019, OR(CI): 6.37(1.54-26.34)) and EDSS scores (p: 0.017), but no difference was found in total annual relapses or relapse rates. COVID-19 infections were positively correlated with EDSS progression (p: 0.02) and the number of new MRI lesions (p: 0.004) and predicted the likelihood of the number of new MRI lesions by an odds of 5.92 (p: 0.018).
COVID-19 may lead to higher disability scores in the RRMS population and is associated with developing new Gd-enhancing lesions in MRI imaging. However, no difference was observed between the groups regarding the number of relapses during follow-up.